Preparation and evaluation of a methyl-PEG2000-DSPE-PVP-LDC nanomaterial: A novel lidocaine delivery system
Source abstract
Abstract
This study investigates the potential of methyl-PEG2000-DSPE-PVP-LDC as a drug delivery nanocarrier and its impact on human immortalized keratinocytes, focusing on cytotoxicity, migration inhibition, and drug-loading efficiency. Synthesized nanoparticles were characterized using scanning electron microscopy, transmission electron microscopy, zeta potential analysis, and Fourier-transform infrared spectroscopy (FTIR). The cytotoxicity in human keratinocyte HaCaT cells and the inhibition of cell migration were analyzed using a scratch assay. Furthermore, the drug-loading efficiency of the nanoparticles was quantified. The synthesized nanoparticles exhibited dimensions under 50 nm, with an optimal size of ∼10 nm for efficient drug loading. The zeta potential was −24.33 ± 2.654 mV. The drug-loading capacity was 226.618 35 µg LDC/mg nanoparticle material. FTIR revealed an interaction between lidocaine and the nanospheres. Cytotoxicity assays indicated that the nanomaterial suppressed the cell cycle progression. In addition, the nanomaterial exhibited a notable inhibition of cell migration, resulting in reduced migration efficiency compared with the control group. Thus, the methyl-PEG2000-DSPE-PVP-LDC nanomaterial demonstrates considerable promise for drug delivery owing to its small particle size, efficient drug-loading capability, and potential to inhibit the proliferation and migration of human immortalized keratinocytes, suggesting its potential diverse biomedical applications, particularly in cancer therapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Guangdong Medical University 1 , Zhanjiang 524000,
Department of Anesthesiology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University 2 , Guangzhou 510317,
Department of General Surgery, Hui Ya Hospital of The First Affiliated Hospital, Sun Yat-sen University 3 , Huizhou, Guangdong 516081,
References (45)
Show source-provided references
1. FASEB J. · 2005 · 19 · 31110.1096/fj.04-2747rev ↗
2. Theranostics · 2023 · 13 · 538610.7150/thno.87854 ↗
3. Biomaterials · 2015 · 72 · 7410.1016/j.biomaterials.2015.08.048 ↗
4. Proc. Natl. Acad. Sci. U. S. A. · 1998 · 95 · 460710.1073/pnas.95.8.4607 ↗
5. J. Nanobiotechnol. · 2018 · 16 · 7110.1186/s12951-018-0392-8 ↗
6. Nat. Biomed. Eng. · 2021 · 5 · 95110.1038/s41551-021-00698-w ↗
7. Nat. Rev. Drug Discovery · 2005 · 4 · 14510.1038/nrd1632 ↗
8. Adv. Drug Delivery Rev. · 2012 · 64 · 31610.1016/j.addr.2012.09.008 ↗
9. Int. J. Pharm. · 2006 · 307 · 9310.1016/j.ijpharm.2005.10.010 ↗
10. Nat. Commun. · 2022 · 13 · 413710.1038/s41467-022-31882-4 ↗
11. Pharmaceutics · 2013 · 5 · 54210.3390/pharmaceutics5040542 ↗
12. Nanomedicine · 2011 · 6 · 71510.2217/nnm.11.19 ↗
13. J. Controlled Release · 1997 · 48 · 19510.1016/s0168-3659(97)00039-4 ↗
14. Methods Appl. Fluoresc. · 2023 · 11 · 03400110.1088/2050-6120/acd837 ↗
15. Clin. Pharmacol. Therapeutics · 2008 · 83 · 76110.1038/sj.clpt.6100400 ↗
16. Mater. Sci. Eng.: C · 2017 · 79 · 10810.1016/j.msec.2017.05.006 ↗
17. Nat. Rev. Mater. · 2021 · 6 · 35110.1038/s41578-020-00269-6 ↗
18. Trends Mol. Med. · 2018 · 24 · 59810.1016/j.molmed.2018.05.003 ↗
19. Curr. Pharm. Biotechnol. · 2021 · 22 · 144410.2174/1389201021666201211103856 ↗
20. JAMA · 2001 · 286 · 221110.1001/jama.286.18.2211 ↗
21. J. Drug Targeting · 2016 · 24 · 17910.3109/1061186x.2015.1051049 ↗
22. J. Nanobiotechnol. · 2024 · 22 · 71410.1186/s12951-024-02954-y ↗
23. Pharmaceutics · 2023 · 15 · 102510.3390/pharmaceutics15031025 ↗
24. Signal Transduction Targeted Ther. · 2024 · 9 · 20010.1038/s41392-024-01889-y ↗
25. J. Controlled Release · 2022 · 345 · 51210.1016/j.jconrel.2022.03.043 ↗
26. NeuroRX · 2005 · 2 · 10810.1602/neurorx.2.1.108 ↗
27. J. Pharm. Biomed. Anal. · 2020 · 183 · 11316310.1016/j.jpba.2020.113163 ↗
28. J. Ethnopharmacol. · 2020 · 260 · 11301710.1016/j.jep.2020.113017 ↗
29. J. Chromatogr. Sci. · 2018 · 56 · 49810.1093/chromsci/bmy021 ↗
30. Eur. J. Immunol. · 2019 · 49 · 145710.1002/eji.201970107 ↗
31. J. Tissue Eng. · 2013 · 4 · 204173141350335710.1177/2041731413503357 ↗
32. Nanoscale · 2013 · 5 · 838410.1039/c3nr01626a ↗
33. Polymers · 2017 · 9 · 32110.3390/polym9080321 ↗
34. Adv. Drug Delivery Rev. · 2016 · 99 · 2810.1016/j.addr.2015.09.012 ↗
35. Angew. Chem., Int. Ed. · 2010 · 49 · 628810.1002/anie.200902672 ↗
36. J. Controlled Release · 2014 · 192 · 6710.1016/j.jconrel.2014.06.046 ↗
37. Bioeng. Transl. Med. · 2016 · 1 · 1010.1002/btm2.10003 ↗
38. Nat. Biotechnol. · 2015 · 33 · 94110.1038/nbt.3330 ↗
39. Mol. Pharm. · 2007 · 4 · 80710.1021/mp700113r ↗
40. Int. J. Pharm. · 2002 · 235 · 17910.1016/s0378-5173(01)00986-3 ↗
41. Enhanced antitumor activity of lidocaine nanoparticles encapsulated by a self-assembling peptide10.3389/fphar.2022.770892 ↗
42. Expert Opin. Drug Metab. Toxicol. · 2012 · 8 · 4710.1517/17425255.2012.637916 ↗
43. Artif. Cells, Nanomed., Biotechnol. · 2016 · 44 · 38110.3109/21691401.2014.953633 ↗
44. ACS Nano · 2010 · 4 · 361110.1021/nn100389a ↗
45. J. Exp. Clin. Cancer Res. · 2011 · 30 · 8710.1186/1756-9966-30-87 ↗